The failure of reproductive success in polycystic ovary syndrome (PCOS) patients could be in part due to endometrial dysfunction. However, no studies have investigated any causality between androgen, androgen receptor (AR) expression, and adenosine monophosphate activated protein kinase (AMPK) activation in the endometrium under physiological and pathological conditions. In the present study, we show that 1) endometrial AR expression levels fluctuate in non-PCOS and PCOS patients during the menstrual cycle; 2) the menstrual phase-dependent alteration of p-AMPKα expression occurs in non-PCOS patients but not in PCOS patients; 3) AR expression is higher in PCOS patients than non-PCOS patients during hyperplasia while AMPKα activation (indicated by the ratio of p-AMPKα to AMPKα); and 4) co-localization of AR and Ki-67 in epithelial cell nuclei is observed in endometrial hyperplasia. Importantly, using in vitro human tissue culture and an in vivo 5α-dihydrotestosterone-treated rat model, we show that the action of androgen on AMPKα activation is likely mediated through nuclear AR, especially in epithelial cells. Collectively, we present evidence that AR expression and AMPKα activation depend on menstrual cycle phase and the presence of PCOS, and the data suggest that AR-mediated regulation of AMPKα activation might play a role in the development of endometrial hyperplasia.
Introduction
Polycystic ovary syndrome (PCOS) is a complex, heterogeneous hormone-imbalance disorder [1] that occurs in approximately 4%-18% of adolescent and reproductive-aged women worldwide [2] . In addition to its negative effects on endocrine activity and metabolism, PCOS has adverse impacts on female reproduction [1, 3] . For example, women with PCOS generally have chronic anovulation, and their endometria tend to remain in a proliferative state due to the lack of counterbalance by progesterone [4] . These defects result in about 75% of PCOS patients suffering from anovulation infertility [5] , and about 50% of Ivyspring International Publisher PCOS patients experience recurrent pregnancy loss [6] . It is generally believed that the failure of reproductive success in PCOS patients could be in part due to endometrial dysfunction [7, 8] .
The human endometrium plays an essential role in menstruation, implantation, pregnancy, and endometrial repair [7] through alterations of epithelial and stromal cell proliferation, differentiation, secretion, and apoptosis [9] . The modulation of different protein expression and signaling pathways has been shown to influence endometrial function [7, 10] . In addition to estrogen and progesterone [10] , androgen is also essential for female reproduction through the activation of androgen receptor (AR), which belongs to a member of the steroid receptor superfamily and regulates transcription of target genes [11] . AR undergoes cyclical changes in expression and has different endometrial cell localization and regulation patterns in women during the menstrual cycle [10, 11] . For example, AR expression in human endometrium is predominantly localized to the stromal cells with maximal expression detected during the proliferative phase of the menstrual cycle [12] [13] [14] [15] [16] . Furthermore, studies undertaken in our laboratory and others have demonstrated that endometrial AR mRNA and protein expression are elevated in PCOS patients compared to non-PCOS patients [12, [17] [18] [19] [20] [21] . Because hyperandrogenism is one of the main clinical complications of PCOS [1, 3] , accumulating evidence suggests that flutamide (an AR antagonist) therapy exerts beneficial ovarian, endocrine, and metabolic effects in PCOS patients [22] [23] [24] [25] [26] [27] . However, an important unanswered question is how androgenic stimulation is involved in the endometrial function in PCOS patients under different phases of menstrual cycle and hyperplasia [28, 29] . Specifically, an understanding of the molecular mechanisms and/or consequences of increased AR expression in the endometrium in women with PCOS remains elusive.
Mammalian adenosine monophosphate-activated protein kinase (AMPK) is a multisubstrate, heterotrimeric serine/threonine kinase that consists of three subunits (α, β, and ɣ) [30] . All three subunits function in unison to modulate cellular metabolism and to control cell growth [31, 32] . The α-subunit in particular has been shown to harbor AMPK activity because the activation of AMPK requires the phosphorylation of threonine 172, which is located within the α catalytic subunit [32] . Although AMPK is expressed in all tissues, accumulating evidence indicates that there is considerable variation in tissue-specific expression, association, and subcellular localization of the individual subunits [33] . However, only AMPKα has been demonstrated in the endometria of women with PCOS and endometrial cancer [34, 35] . Furthermore, while hormonal, nutrient, and metabolic stress signals regulate AMPK activation and its activity in multiple peripheral tissues such as liver, skeletal muscle, and adipose tissues [32, 36] as well as different cancer cells [37] , to our knowledge no studies have investigated any causality between androgen, AR expression, and AMPK activation in the endometrium under physiological and pathological conditions.
The aims of the present study, therefore, were to investigate the temporal and spatial expression patterns of AR, p-AMPKα, AMPKα, and Ki67 (a cellular marker for proliferation) in the endometrium of PCOS patients in different phases of the menstrual cycle or with hyperplasia. In addition, the effect of 5α-dihydrotestosterone (DHT) and flutamide on the regulation of AR, p-AMPKα, and AMPKα expression was investigated with in vitro human tissue culture and an in vivo rat model.
Materials and methods

Reagents and antibodies
DHT (a specific AR agonist, D-5027), flutamide (a specific AR antagonist, F-0397), and diaminobenzidine (DAB) were from Sigma-Aldrich (St. Louis, MO). Avidin-biotinylated-peroxidase complex detection system (ABC kit) was from Vector Laboratories Inc. (Burlingame, CA). All antibodies were from the following sources: AR (#5153, this antibody reacts with human tissues), AMPKα (#2532), phospho-AMPKα (phosphorylated threonine 172, #2535), and Ki-67 (#11882) antibodies were from Cell Signaling Technology (Danvers, MA); AR (sc-816, this antibody reacts with rodent tissues) and p21 Cip1 antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA); and cysteine-rich protein 61 (CYR61, HPA029853) antibody was from Sigma-Aldrich. Anti-mouse IgG horseradish peroxidase (HRP)-conjugated goat (A2304) and anti-rabbit IgG HRP-conjugated goat (A0545) secondary antibodies were from Sigma-Aldrich. Alexa Fluor 594-conjugated goat polyclonal anti-mouse IgG, and Alexa Fluor 488-conjugated goat polyclonal anti-rabbit IgG were from Invitrogen (Life Technologies Europe BV, Stockholm, Sweden).
Patients and tissue collection
This investigation was approved by the institutional ethical review board of the Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China, and signed informed consent for use of the samples was obtained from all patients. All endometrial tissues were obtained by endometrial curettage of the bisected uteri obtained during hysterectomy for benign gynecological indications. Each endometrial sample was diagnosed and staged by routine pathology analysis based on standard histological criteria [38] , and the patient's last reported menstrual period was recorded at the time of collection [39] . Immunohistochemical staining of cysteine-rich 61 (Cyr61) with a confirmed histological diagnosis of simple or complex endometrial hyperplasia without cytological atypia was performed (Fig. 1) . All fertile women (n = 45, aged 25-51 years) at the proliferative (n = 19) or secretory phases of the menstrual cycle (n = 15) or with hyperplasia (n = 11) taking part in the investigation had regular menstrual cycles and showed no evidence of any pathological uterine disorder. Endometrial biopsies at different stages of the menstrual cycle were obtained from PCOS patients (n = 14, aged 28-36 years) at the proliferative (n = 9) and secretory phases of the menstrual cycle (n = 2) or with hyperplasia (n = 3). PCOS was diagnosed based on the Rotterdam criteria provided by the American Society for Reproductive Medicine and the European Society for Human Reproduction and Embryology [40] . All PCOS patients were diagnosed according to at least two of the following criteria: 1) oligo/anovulation, 2) signs of hyperandrogenism (i.e., hirsutism and acne) and/or biochemical measurements, or 3) enhanced ovaries (at least 12 discrete follicles of 2-9 mm in diameter in one ovary or an ovarian volume >10 cm 3 observed by transvaginal ultrasonography). No PCOS patients presented congenital adrenal hyperplasia, Cushing's syndrome, thyroid hormone abnormalities, hyperprolactinemia, or ovarian/adrenal tumors. None had any history of previous first-trimester miscarriage or pregnancy. Neither non-PCOS nor PCOS subjects were exposed to hormonal medication for at least three months prior to tissues sampling [8] . Human endometrial tissues were fixed in formalin and embedded in paraffin, and immunohistochemistry was performed. It was reported that the expression of Cyr61, a cysteine-rich secreted heparin-binding protein, was significantly increased in the endometrium of PCOS patients with hyperplasia compared to age-matched, non-PCOS patients with normal menstrual cycles, and it appears to be a useful tissue biomarker for the detection of endometrial hyperplasia. Therefore, we used Cyr61 protein expression to verify that the endometrial samples had come from non-PCOS and PCOS patients. Representative images from three independent experiments are shown. The histology of hematoxylin/eosin-stained human endometrial biopsy samples is indicated. GE, glandular epithelial cells; Str, stromal cells.
Primary in vitro tissue culture
Tissue culture was essentially carried out as described previously [21, 39] . Briefly, endometrial tissues from each woman in the proliferative phase of a normal menstrual cycle were treated with DHT (100 nM) and were incubated in a humidified incubator (37°C, 95% O 2 , 5% CO 2 ) for 24 h. On the second day, the tissues were further treated with DHT (100 nM) or DHT (100 nM) plus flutamide (10 μM) and were cultured for an additional 24 h. The selected doses of DHT and flutamide were according to previous studies [41, 42] . DHT and flutamide were dissolved in 100% ethanol at a concentration of 50 mM and added to culture medium to achieve the desired final concentration. Controls were treated with 100% ethanol. At the end of the experiments, tissues were washed with ice cold PBS and were snap-frozen in liquid nitrogen and stored at −70°C.
Hormonal treatment in animals
This study was approved by the Animal Ethics Committee of the University of Gothenburg, Sweden. Prepubescent female Wistar rats obtained from Charles River (Sulzfeld, Germany) were used to avoid both the effects of endogenous estrogen and the surgical procedures such as ovariectomy that would be necessary to remove the main source of endogenous steroid hormone production. Rats (n = 18) were randomly treated with vehicle only (control) or with DHT (Sigma-Aldrich, St. Louis, MO). There were nine animals in each experimental group. At 21 days of age, rats were treated with daily subcutaneous injections of 100 μl sesame oil vehicle or DHT (1.66 mg/kg in 100 μl sesame oil) for one week [43] . The dose and time of DHT injection has previously been shown to suppress hypothalamic AR expression in both female and male rats [43, 44] . Animals were housed in a room under defined conditions (e.g., 21-22°C, 55-65% humidity and a 12 hour light/dark cycle). Rats had free access to tap water and were fed ad libitum with standard rodent chow. All animals were allowed to acclimate to the animal facilities for at least five days before initiation of the treatment and experiment. Under anesthesia, the uterine tissues were collected and fixed in 4% formaldehyde neutral buffered solution for 24 h at 4°C and embedded in paraffin for histochemical analysis.
Western blot analysis
Endometrial and uterine tissues were extracted according to the previous studies [21, 39] . A detailed explanation of the Western blot analysis and membrane stripping protocol has been published elsewhere [45] . Equal amounts of protein for each treatment group were resolved on NuPAGE 4-12% Bis-Tris gels (Invitrogen) and transferred onto PVDF membranes. The primary antibodies (1:1000-2000 dilution) were used. The specificity of AR antibodies (#5153 and sc-816) is shown in Figure 2 .
Immunohistochemistry
The tissues were fixed in 4% formaldehyde neutral buffered solution for 24 h at 4°C. Following paraffin embedding and sectioning (5 μm), sections were stained with hematoxylin and eosin (H&E). Two different methods of immunohistochemistry were performed using human endometrial and rat uterine tissues. 3,3-Diaminobenzidine tetrahydrochloride (DAB) immunohistochemistry [46] and dual-immunofluorescence assays [47] were based on the previously described methodology. The primary antibodies anti-AR (1:200 dilution) and anti-CYR61 (1:30 dilution) were used for DAB immunohistochemistry. The primary antibodies anti-AR (1:50 or 1:200 dilution) and Ki-67 (1:50 dilution) were used for immunofluorescence assay.
Statistics
Numerical, grouped results are presented as means ± SEM. All data were analyzed using one-way or two-way ANOVA followed by Dunnett's post-hoc tests. For the in vivo study, two-way ANOVA was used to assess the main effects of menstrual cycle phase/endometrial hyperplasia and PCOS and to identify the interactions between them. A p-value less than 0.05 was considered statistically significant. Statistical analyses were performed using SPSS version 21.0 statistical software for Windows (SPSS Inc., Chicago, IL).
Results
Regulation of endometrial AR expression in women regardless of PCOS condition was menstrual phase-dependent and cell type-dependent
Western blot analysis showed that the levels of AR were lower in the secretory phase than the proliferative phase of the menstrual cycle in non-PCOS and PCOS patients and that AR protein expression was higher in PCOS patients with hyperplasia than non-PCOS patients with hyperplasia (Fig. 3A) . In addition, although a tendency toward increased AR expression level did not result in a significant difference between non-PCOS and PCOS patients, the number of AR-positive cases was higher in PCOS patients in the proliferative phase (9/9, 100%) than non-PCOS patients in the proliferative phase (10/15, 66.67%). The number of AR-positive cases was similar in the secretory phase between non-PCOS (8/15, 53.33%) and PCOS (1/2, 50%) patients. Immunohistochemical analysis revealed weak and heterogeneous positive nuclear staining for AR in the epithelial cells in non-PCOS patients in the proliferative phase ( Fig. 3B1 and B2) compared to non-PCOS patients in the secretory phase ( Fig. 3D1 and D2 ) and to PCOS patients in all phases (Fig. 3C1, C2 , E1, and E2). This nuclear distribution of AR in the epithelial cells was confirmed by immunofluorescence assay (data not shown). In line with the Western blot analysis, although AR was predominately localized in the stromal cells, an intense overall AR immunoreactivity was detected in the proliferative phase compared to the secretory phase of the menstrual cycle in non-PCOS patients (compare Fig. 3B1 and B2 to Fig. 3D1 and D2) . In contrast, similar levels of AR immunoreactivity were seen between the proliferative (Fig. 3C1 and C2 ) and secretory ( Fig. 3E1 and E2 ) phases in PCOS patients.
Nuclear AR expression was increased in the epithelial cells in PCOS patients with hyperplasia
With endometrial hyperplasia, a significant increase in AR protein level was identified in PCOS patients compared to non-PCOS patients (Fig. 3A) . The number of AR-positive cases was 4/11 (36.36%) in non-PCOS patients with hyperplasia and 3/3 (100%) in PCOS patients with hyperplasia. In contrast to non-PCOS patients with hyperplasia ( Fig. 3F1 and  F2 ), increased nuclear AR expression was detected in the epithelial cells in PCOS patients with hyperplasia although the number of epithelial AR-positive cells and the intensity of the immunoreactivity were variable ( Fig. 3G1 and G2 ). To gain insights into the androgen-dependent in vivo regulation of nuclear expression of AR in PCOS patients with hyperplasia, an immunofluorescence assay was performed with uterine tissues from prepubescent rats treated with DHT. We found that while AR was expressed in the epithelial and stromal cells in the prepubescent rat uterus (Fig. 4A1-A4 ), treatment with DHT increased nuclear AR expression in the uterine cells, especially in the luminal epithelial cells (Fig. 4B1-B4 ). 
p-AMPKα and AMPKα were widely expressed in both epithelial and stromal cells, but only regulation of p-AMPKα was menstrual phase-dependent and cell type-dependent
Using the same human endometrial biopsies, Western blot analysis revealed that the levels of p-AMPKα (phosphorylated threonine 172) were higher in the secretory phase than the proliferative phase of the menstrual cycle in non-PCOS patients; however, the levels of p-AMPKα failed to change in PCOS patients during the menstrual cycle (Fig. 5) . In addition, there were no significant changes in AMPKα protein levels at different phases of the menstrual cycle in women regardless of PCOS or hyperplasia conditions (Fig. 5) . We found that the ratio of p-AMPKα to AMPKα was higher in PCOS patients than non-PCOS patients in the proliferative phase. In contrast, the ratio of p-AMPKα to AMPKα was lower in PCOS patients than non-PCOS patients under hyperplasia conditions (Fig. 5) .
Both p-AMPKα and AMPKα immunoreactivities were detected in the cytosol and nuclei of the endometrial cells. Although p-AMPKα (Fig. 6A1-F1) and AMPKα (Fig. 6A2-F2 ) were expressed in epithelial and stromal cells in women regardless of PCOS or hyperplasia conditions significantly higher levels of immunoreactivity of p-AMPKα (Fig. 6B1) and AMPKα (Fig. 6B2) were detected in the epithelial cell nuclei in PCOS patients in the proliferative phase of the menstrual cycle. There were no obvious changes to the immunoreactivity of stromal p-AMPKα (Fig.  6A1-F1 ) and AMPKα ( Fig. 6A2-F2 ) expression in non-PCOS and PCOS patients. To determine the specificity of the primary antibody, immunohistochemical analysis was performed using only secondary antibodies (Fig. 6G ). In line with the human results, increased expression of p-AMPKα (Fig. 7A1-B2 ) and AMPKα (Fig. 7C1-D2 ) was also observed in luminal epithelial cell nuclei in the uteri of rats treated with DHT.
Activation of AR by DHT increased p21 Cip1 expression, and suppression of AR with flutamide decreased p-AMPKα expression
In order to mimic the hyperandrogenism in PCOS patients, endometrial tissues were collected from non-PCOS patients in the proliferative phase (high levels of endogenous estrogen) and treated with 100 nM DHT. After 24 h, the tissues were further treated with 100 nM DHT, 100 nM DHT combined with 10 μM flutamide (an AR antagonist), or vehicle for an additional 24 h (Fig. 8A) . p21 Cip1 is considered to be an androgen-regulated response gene because its promoter contains an androgen response element [48] . Western blot analysis showed that DHT treatment increased AR and p21 Cip1 expression, and the addition of flutamide abolished the DHT-induced AR and p21 Cip1 expression (Fig. 8B) . Although there was a tendency for an increase in p-AMPKα expression in the endometrial tissues treated with DHT, a significant decrease in p-AMPKα expression was observed upon addition of flutamide (Fig. 8B) . Neither AMPKα expression nor ratios of p-AMPKα to AMPKα were affected by treatment with DHT and/or flutamide (Fig. 8B) . 
Regulation of endometrial Ki-67 expression was dependent on menstrual cycle phase and it was co-localized with AR in epithelial cells under hyperplasia conditions
An immunofluorescence assay showed that the nuclear protein Ki-67, a cellular marker for proliferation, was present in both epithelial and stromal cells at all phases of the menstrual cycle (data not shown). The number of Ki-67-positive cells was affected by the phase of the menstrual cycle in non-PCOS and PCOS patients. Furthermore, the number of Ki-67-positive epithelial cells was lower in PCOS patients than non-PCOS patients in the secretory phase of the menstrual cycle (Fig. 9A) . There was also a decreased number of Ki-67-positive epithelial cells in PCOS patients with hyperplasia compared to non-PCOS patients with hyperplasia (Fig. 9A) . Under hyperplasia conditions, the numbers and immunoreactivity of AR-positive epithelial cells were higher in PCOS patients (Fig. 9C1 and C2 ) than non-PCOS patients ( Fig. 9B1 and B2) , which is in agreement with the immunochemical analysis (Fig. 3 F1-G2 ). In addition, a dual-immunofluorescence assay revealed that Ki-67 was co-localized with AR in epithelial cells under hyperplasia conditions in both non-PCOS ( Fig.  9B1 and B2 ) and PCOS ( Fig. 9C1 and C2) patients.
There was no co-localization between Ki-67 and AR in epithelial cells in PCOS patients without hyperplasia ( Fig. 9D1 and D2 ). This suggests that Ki-67 expression was not dependent on androgenic regulation in the endometrial epithelial cells.
Discussion
Interactions between androgens, AR expression, and AMPK activation have been reported in other tissues and cells [49] [50] [51] , but have not been investigated in human endometrium under pathophysiological conditions. This study identifies a link between the effects of androgen on endometrial AR expression and AMPKα activation in non-PCOS and PCOS patients during the menstrual cycle and/or with endometrial hyperplasia. We show that 1) endometrial AR expression levels fluctuate in non-PCOS and PCOS patients during the menstrual cycle; 2) the menstrual phase-dependent alteration of p-AMPK expression occurs in non-PCOS patients but not in PCOS patients; 3) AR expression is higher in PCOS patients than non-PCOS patients during hyperplasia while AMPKα activation (indicated by the ratio of p-AMPKα to AMPKα); and 4) the action of androgen on AMPKα activation is likely mediated through nuclear AR, especially in epithelial cells. Endometrial tissues from the proliferative phase of healthy women (n = 4) were treated with 100 nM DHT (an AR agonist). After 24 h, the culture media with DHT were removed and the endometrial explants were treated with 100 nM DHT or 100 nM DHT + 10 μM flutamide (fluta, an AR antagonist) for 24 hours. Culture media without DHT served as controls (vehicle). Representative Western blot analysis of AR, p21 Cip1 , p-AMPK, and AMPK expression (B) was performed as described in the Materials and Methods. Values are expressed as mean ± SEM. ** p < 0.05 compared to vehicle; # p < 0.05 compared to DHT.
Regulation of endometrial AR expression in non-PCOS and PCOS patients
Our observation of increased AR expression in the endometrium in PCOS patients is broadly in agreement with previous reports [12, [17] [18] [19] [20] [21] . However, these studies did not determine whether the different phases of the menstrual cycle influence AR expression in PCOS patients. In fact, we did observe a cyclical fluctuation of AR expression in PCOS patients, although the level of AR expression was always higher in PCOS patients than non-PCOS patients. It is realized that the regulation of AR expression might vary and that different complexes of subunits might form in different tissues/cells. Common opinion holds that androgens are the primary regulators of AR expression and activation [11] ; however, previous studies show that the high levels of AR are associated with the proliferative phase of the menstrual cycle [12] [13] [14] [15] [16] and that AR expression is also regulated by estrogens in human endometrium [52, 53] . While endogenous androgen levels [1, 3] and endometrial P450 aromatase expression [54] are significantly increased in PCOS patients, it is likely that both androgen and estrogen contribute to increased endometrial AR expression in PCOS patients. However, under the estrogen-related hyperplasia condition we observed a significant increase in AR expression in PCOS patients compared to non-PCOS patients. Therefore, our findings indicate that androgens might play a major role in up-regulating endometrial AR protein synthesis in PCOS patients. Several molecules have been shown to display a cell specific and/or temporal expression pattern in the endometrium under physiological and pathological conditions [9, 55] , and our localization data for AR in stromal cells in PCOS patients are consistent with previous studies [12, 20] . Endometrial AR has several proposed, but no proven, roles in human reproductive function. For instance, data from in vitro studies using the endometrial stromal cell culture suggest that the androgen-induced AR activation might participate in the anti-proliferative process against estrogen and in uterine receptivity to embryo implantation [11] . Furthermore, genetic models of loss of function of AR have demonstrated that female mice suffer from defective implantation and reduced fertility due to improper development of the uterus [56] . Therefore, it is possible that the high levels of anti-proliferative AR in the stromal cells are involved in the implantation failure and recurrent miscarriage in women with PCOS. On the other hand, DHT-induced AR expression has been shown in well-differentiated epithelial cells (Ishikawa cells) in vitro but not in isolated human endometrial stromal cells [12] . While AR is present in human endometrial epithelial cells in the proliferative phase of the menstrual cycle in vivo [ [10] , the present study] and in vitro [57] , we observed that AR immunoreactivity was increased in particular in the epithelial cell nuclei in PCOS patients with endometrial hyperplasia. Endometrial hyperplasia is a known precursor of and marker for concurrent endometrial cancer [28] , which originates in the endometrial epithelial cells [58] . It has been reported that 70% of endometrial cancer are AR positive [14] , and AR immunoreactivity can be detected in PCOS patients with endometrial cancer (data not shown). Thus, we speculate that the function of epithelial AR might differ from stromal AR in the endometrium and that the activation of epithelial AR might critically affect epithelial cell transformation and endometrial cancer development.
AR-mediated AMPKα activation in non-PCOS and PCOS patients
In this study, we used Western blot and immunohistochemical analyses to evaluate the expression levels of p-AMPKα and AMPKα in the endometrium under physiological and pathological conditions. We show that the active form of AMPKα, p-AMPKα, but not AMPKα, is significantly regulated in non-PCOS patients in a menstrual phase-dependent manner. Our analysis detected no significant changes in either p-AMPKα or AMPKα expression in the endometrium in PCOS patients. This does not dispute the importance of AMPKα activation in the endometrium under disease condition. However, it does reveal that the endometrial p-AMPKα/AMPKα ratio was increased in the proliferative phase of the menstrual cycle in PCOS patients compared to non-PCOS patients and it was decreased in PCOS patients with endometrial hyperplasia compared to non-PCOS patients during the secretory phase (Fig. 5) .
The direct effects of androgen on AMPKα expression and activation have been described in prostate cancer cells in vitro [37] . Within the in vitro experiments of this study, we demonstrate the androgen-dependent regulation of AR expression and AMPKα activation in the endometrium. Unfortunately, we are unable to observe a significant effect of DHT treatment on the increased p-AMPKα expression in human endometrium in vitro, which mimics hyperandrogenism in PCOS patients in vivo. Because androgens can exert their effects through cell-membrane bound ARs [59] , our findings do not rule out the possibility that AMPKα activation is dependent on acute (nongenomic) androgen stimulation in the endometrial cells. Interestingly, our data show that adding the AR antagonist flutamide along with DHT inhibits the androgenic effect of the DHT. Increased AR might function through modulation of various downstream targets such as the cell cycle regulator p21 Cip1 to influence endometrial cell proliferation and apoptosis [60] .
The possible role of AMPKα activation in the endometrium
AMPK contributes to the regulation of cellular metabolism and limits cell growth [31, 32] . Although a physiological implication of AMPKα activation in the endometrium is uncertain [29] , we show that endometrial AMPKα activation is decreased in PCOS patients with hyperplasia compared to PCOS patients without hyperplasia. The fact that there is a similar expression pattern between p-AMPKα (the present study) and p21 Cip1 [60] in human endometrial epithelial cells during the menstrual cycle and that activation of the AMPK complex (αβɣ units) modulates cell cycle progression through induction of p21 Cip1 [31] suggests the possibility that inhibition of AMPKα activation blocks cell cycle progression by suppressing p21 Cip1 expression. Such inhibition of AMPKα would result in increased cell proliferation and hyperplasia in PCOS patients; however, further investigations are needed to test such a possibility.
In this study, we also demonstrate that p-AMPKα and AMPKα expression is primarily in the cytosolic and nuclear endometrial cells and that the immunoreactivities to these molecules are greater in the epithelial cell nuclei of PCOS patients than non-PCOS patients and in rats treated with DHT. Our results are in agreement with the subcellular localization data obtained by Schuler et al. [35] but are in contrast to the results obtained by Carvajal et al. [34] . The nuclear localization of p-AMPKα and AMPKα is not surprising because the antibodies against p-AMPKα and AMPKα used this study can detect both the α1 and α2 isoforms. In fact, in cells the AMPKα1 isoform appears to be dominantly expressed in the cytosol whereas the AMPKα2 isoform is largely localized in the nuclei [33] . Importantly, studies of mutant mice lacking various AMPKα isoforms suggest that AMPKα2, but not AMPKα1, is essential for energy metabolism and insulin sensitivity [36] . Future studies are needed to clarify the functional differences between the two AMPKα isoforms in the endometrium.
Conclusion
Clinical evidence indicates that high expression of AR might contribute to PCOS pathogenesis [61] . In order to develop effective treatments for the endometrial dysfunction seen in women with PCOS, it is important to understand exactly how androgen-AR signalling leads to different molecular changes in the endometrium and to endometrium-related reproductive outcomes in these patients. In conclusion, our data add novel descriptive insights into AR expression and AMPKα activation in women under physiological and pathological conditions. We report for the first time that AR expression and AMPKα activation depend on menstrual cycle phase and the presence of PCOS, and AR-mediated regulation of AMPKα activation might play a role in the development of endometrial hyperplasia in women with PCOS.
